



## Progress In Epidermolysis Bullosa DEBRA Symposium at SID

FRIDAY, MAY 10, 2019

7:00 PM - 10:00 PM

CONTINENTAL BALLROOM C

(Organized by Angela Christiano, Brett Kopelan and Jouni Uitto)

### PROGRAM

1. **Cristina Has** (Freiburg University)  
**Update of Classification and Nomenclature of EB: Summary of the 2019 DEBRA International Consensus Meeting**
2. **Bahar Dageb** (Thomas Jefferson University)  
**The DEBRA Adult EB and Complex Skin Cancer Clinic: The Jefferson Experience**
3. **Alain Hovnanian** (Necker-Enfants Malades Hospital, Paris)  
**Research Advances Towards Treatment and Cure of EB**
4. **Abstract Presentations on Cutting Edge EB Research**
  - Marcel F. Jonkman In Memoriam Abstract**  
**Yenamandra et al.** (University Medical Center Groningen, The Netherlands)  
Abstract #414  
**Uncovering the cause of early lethality in generalized severe junctional epidermolysis bullosa**
  - Twariski & Tolar (University of Minnesota, USA)**  
Abstract #396  
**Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa**
  - Torkelson et al.** (University of Colorado, USA)  
Abstract #1036  
**Scalable production of CRISPR-corrected autologous iPSC derived skin grafts to treat epidermolysis bullosa**
5. **Brett Kopelan** (DEBRA of America)  
**Future Treatments of EB: Industry Panel Discussion**

Refreshments served.

Funding for this symposium is provided by: Amryt Pharma, Berg Health, Castle Creek Pharma, Constant Therapeutics, Fibrocell Science, Innova Therapeutics, Krystal Biotech, and ProQR